Biotest : Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation (News)

News: Biotest AG / Key word(s): Research Update
Biotest AG: Pentaglobin(R) showed encouraging results in the treatment of
donor specific antibodies after lung transplantation

14.01.2016 / 09:00
The issuer is solely responsible for the content of this announcement.

/
PRESS RELEASE

Pentaglobin(R) showed encouraging results in the treatment of donor
specific antibodies after lung transplantation

- In lung transplantation early new donor specific antibodies (DSA) are
risk factors for mortality and graft rejection

- Pentaglobin showed very good efficacy in patients who showed early DSA
development after lung transplantation

- Patients with early new DSA but treated with Pentaglobin(R) have
midterm survival and lung function comparable to patients not
developing DSA at all

- Relative mortality rate reduction of over 70%

Dreieich, 14 January 2016. In lung transplantation early new donor specific
antibodies (DSA) are risk factors for mortality, and acute and chronic
graft rejection. About 20-30% of all lung transplantation patients develop
DSA. Hence, DSA treatment seems to be justified albeit to date, no standard
treatment is established in lung transplantation. In a recently published
study conducted in Hannover Medical School, Germany, it was shown that
patients treated with Pentaglobin(R) (IgM / IgA enriched immunoglobulin)
with early DSA development after lung transplantation had a significantly
higher survival rate than patients treated with therapeutic plasma
exchange.

In the Pentaglobin(R) group (56 patients) the survival rate of 94% after
one year was comparable to patients without DSA (180 patients) and much
higher than in the historic therapeutic plasma exchange group (57 patients)
with a survival rate of 79%. Already after one year the relative mortality
rate was reduced more than 70%.

'The magnitude of the difference between the two treatment strategies was
more pronounced than we expected. The mortality risk caused by DSA after
lung transplantation was significantly reduced with IgM / IgA enriched
immunoglobulin.' stated Prof Dr Gregor Warnecke, principle investigator of
the study.

Pentaglobin(R) therapy yielded superior DSA clearance (92%), which
persisted long term and was significantly better than that in therapeutic
plasma exchange treated patients (64%). Additionally the Pentaglobin(R)
patients showed less infections requiring hospitalization and improved
early freedom from bronchiolitis obliterans syndrome (inflammatory disease
of the small airways, in which a scarring process leads to a progressive
closure), major cause for graft failure and re-transplantation.

These encouraging results justify evaluating the potential of IgM / IgA
enriched immunoglobulins in additional indications. Biotest has recently
completed a phase II trial for the newly developed IgM / IgA enriched IgM
Concentrate (BT-086) and is currently planning the further development in a
phase III trial.

About Pentaglobin(R)
Pentaglobin(R) is the first and only IgM-enriched immunoglobulin
preparation for intravenous use. Pentaglobin(R) significantly increases the
survival rate of patients with severe bacterial infections and acts against
a broad spectrum of bacterial pathogens. Pentaglobin's(R) mode of action,
is both anti-bacterial by fast neutralization of bacterial endo- and
exotoxins and anti-inflammatory by scavenging excessively activated
complement factors. Pentaglobin(R) is licensed in several countries, mainly
for the treatment of severe bacterial infections in combination with
antibiotics.

About Biotest
Biotest AG is a provider of plasma proteins and biological drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indication cancer of plasma cells and systemic lupus erythematosus
(SLE), which are produced by recombinant technologies. Biotest has more
than 2,200 employees worldwide. The preference shares of Biotest AG are
listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: [phone],
email: [e-mail]

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

14.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [e-mail]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg,
Stuttgart

End of News DGAP News Service

428637 14.01.2016